The creation of retatrutide, a novel dual activator targeting both GLP-1 and GIP receptors, represents a complex multi-step organic process. Preliminary routes focused on peptide fragment coupling, utilizing solid-phase synthesis methodologies to build the long peptide sequence. Subsequent study has explored alternative approaches, including enzyma